WallStSmart
HURA

TuHURA Biosciences Inc

NASDAQ: HURA · HEALTHCARE · BIOTECHNOLOGY

$2.40
-10.27% today

Updated 2026-06-05

Market cap
$125.14M
P/E ratio
P/S ratio
EPS (TTM)
$-0.61
Dividend yield
52W range
$0 – $4
Volume
0.9M

TuHURA Biosciences Inc (HURA) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item201020112012201420152016201720182019202020212022202320242025
Revenue$0.00$0.00$0.00$0.00
Revenue growth (YoY)
Cost of revenue$10288.00$16683.00$24528.00$16348.00$10000.00$32000.00$60000.00$60000.00$55000.00$116710.00
Gross profit$-10288.00$-16683.00$-24528.00$-16348.00$-10000.00$-32000.00$-60000.00$-60000.00$-55000.00$-116710.00
Gross margin
R&D$2.34M$2.56M$3.36M$5.00M$7.13M$3.66M$3.63M$11.81M$15.17M$9.31M$2.66M$13.34M
SG&A$2.38M$2.01M$4.14M$4.31M
Operating income$-5582.00$-33136.00$-18885.00$-6.29M$-4.72M$-6.21M$-8.32M$-11.17M$-8.40M$-8.14M$-21.57M$-22.68M$-14.80M$-8.45M$-17.65M
Operating margin
EBITDA$-5582.00$-33136.00$-18885.00$-8.28M$-4.35M$-8.85M$-8.07M$-11.11M$-8.03M$-9.12M$-38.15M$-22.62M$-14.74M$-8.27M$-17.43M
EBITDA margin
EBIT$-5582.00$-33136.00$-18885.00$-6.29M$-4.72M$-8.86M$-8.08M$-11.14M$-8.05M$-9.13M$-38.18M$-22.68M$-14.80M$-8.32M$-17.54M
Interest expense$8020.00$2091.00$120000.00$629286.00$0.00$18688.00$4.14M
Income tax$-1.00
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-5582.00$-33136.00$-18885.00$-8.29M$-4.35M$-8.86M$-8.08M$-11.14M$-8.05M$-9.13M$-38.30M$-22.66M$-14.65M$-8.32M$-21.68M
Net income growth (YoY)-493.6%+43.0%-43800.9%+47.6%-103.9%+8.8%-37.8%+27.7%-13.4%-319.7%+40.8%+35.4%+43.2%-160.6%
Profit margin

Frequently asked questions

How much free cash flow does HURA generate?

HURA produced $-14.79M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is HURA's balance sheet healthy?

HURA holds $12.66M in cash and equivalents against — in long-term debt, on $14.59M of shareholder equity. That debt is best read against the cash flow the business throws off each year.